HLS Therapeutics Inc. (OTCMKTS:HLTRF) Sees Significant Decline in Short Interest

HLS Therapeutics Inc. (OTCMKTS:HLTRF) was the target of a large drop in short interest in September. As of September 30th, there was short interest totaling 100 shares, a drop of 93.5% from the September 15th total of 1,546 shares. Based on an average trading volume of 927 shares, the short-interest ratio is currently 0.1 days.

Wall Street Analyst Weigh In

Separately, Raymond James Financial raised shares of HLS Therapeutics from an “outperform” rating to a “strong-buy” rating in a report on Thursday, August 13th. One investment analyst has rated the stock with a Strong Buy rating. According to data from MarketBeat.com, the company currently has a consensus rating of “Strong Buy”.

HLS Therapeutics Price Performance

Shares of OTCMKTS HLTRF remained flat at $2.75 during trading hours on Friday. The business has a 50 day simple moving average of $2.78 and a 200-day simple moving average of $3.03. HLS Therapeutics has a 52-week low of $2.64 and a 52-week high of $4.02.

About HLS Therapeutics

HLS Therapeutics Inc is a specialty pharmaceutical company focused on acquiring, developing and commercializing medicines in Canada and the United States. The company concentrates on products that address significant medical needs, with an emphasis on central nervous system and cardiovascular therapies.

HLS has commercialized branded prescription medicines and specialty products through partnerships, licensing arrangements and acquired product rights. Its portfolio has included Clozaril (clozapine), a treatment used in schizophrenia, as well as other therapies marketed through specialty-care and hospital channels.